Drugs / PF-03882845
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01488877 | Jan → Jul 2012 | diabetic kidney disease | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT01445860 | Aug → Sep 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01314898 | Mar → Jun 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01366287 | Jan → Feb 2011 | type 2 diabetes mellitus | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00971802 | Sep 2009 → Feb 2010 | — | Pfizer | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00856258 Comparator | Mar → Jun 2009 | — | Pfizer | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF 03882845 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00856258 ↗ |
| Known as | CHEMBL1215331 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1215331 ↗ |
| Known as | PF-3882845 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1215331 ↗ |
| Action | Inhibit | “Mineralocorticoid receptor antagonist” CHEMBL1215331 ↗ |
| Modality | Small molecule | — CHEMBL1215331 ↗ |
| Route | Oral | “Oral Multiple Dose Trial” NCT00856258 ↗ |
| Target | NR3C2 | “Mineralocorticoid receptor antagonist” CHEMBL1215331 ↗ |